Pharmaceutical companies' U.S. revenue growth slows by 5% in 2027

Market overview

Trump's most favored nation policy and potential legislative caps on drug prices would directly reduce revenue for U.S. pharma companies. The policy aims to align prices with lower international rates, likely leading to a measurable slowdown in revenue growth.

earnings prediction market

Implied probability (Yes)

75%

Source: user-generated

More earnings markets

• Will cash burn exceed $5M in Q4? — 65% Yes
• Will Venyra beat Q4 2026 revenue consensus of $230M? — 85% Yes
• Will Nuburu secure emergency financing by Q3 end? — 35% Yes
• Will Everpure, Inc. report a non-GAAP EPS beat for the quarter ended June 30, 2026? — 50% Yes
• Will KR miss Q4 operating margin guidance? — 65% Yes
• Will George Risk report Q4 2026 revenue above $13M? — 85% Yes
• Will DCI beat Q4 EPS consensus of $0.88? — 65% Yes
• Will inventory days decrease below 70 by year-end? — 40% Yes

Browse all earnings markets →